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ABSTRACT Vascular endothelial growth factor A (VEGF-A) regulates many aspects of vascu-
lar physiology. VEGF-A stimulates signal transduction pathways that modulate endothelial 
outputs such as cell migration, proliferation, tubulogenesis, and cell–cell interactions. Multi-
ple VEGF-A isoforms exist, but the biological significance of this is unclear. Here we analyzed 
VEGF-A isoform–specific stimulation of VCAM-1 gene expression, which controls endotheli-
al–leukocyte interactions, and show that this is dependent on both ERK1/2 and activating 
transcription factor-2 (ATF-2). VEGF-A isoforms showed differential ERK1/2 and p38 MAPK 
phosphorylation kinetics. A key feature of VEGF-A isoform–specific ERK1/2 activation and 
nuclear translocation was increased phosphorylation of ATF-2 on threonine residue 71 (T71). 
Using reverse genetics, we showed ATF-2 to be functionally required for VEGF-A–stimulated 
endothelial VCAM-1 gene expression. ATF-2 knockdown blocked VEGF-A–stimulated VCAM-
1 expression and endothelial–leukocyte interactions. ATF-2 was also required for other 
endothelial cell outputs, such as cell migration and tubulogenesis. In contrast, VCAM-1 was 
essential only for promoting endothelial–leukocyte interactions. This work presents a new 
paradigm for understanding how soluble growth factor isoforms program complex cellular 
outputs and responses by modulating signal transduction pathways.
INTRODUCTION
The 58 human receptor tyrosine kinases (RTKs) can be classified into 
20 subfamilies, which regulate animal development, health, and dis-
ease (Lemmon and Schlessinger, 2010). These type I membrane 
proteins contain an extracellular ligand-binding domain that “trans-
mits” information through a transmembrane domain to a cytoplas-
mic tyrosine kinase domain. Ligand binding triggers tyrosine kinase 
domain activation, with subsequent transautophosphorylation 
within RTK dimers, recruitment, and phosphorylation of different 
signal transduction enzymes and substrates. Targeting RTK activity 
for therapeutic gain is complicated due to the increasing number of 
soluble and membrane-bound ligands.
Such complexity is exemplified by the vascular endothelial 
growth factor (VEGF) family. These ligands bind class III RTKs (VEGF 
receptors 1–3 [VEGFR1–3]) and coreceptors such as neuropilins 
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human endothelial cells (Figure 1C). We first compared VCAM-1 
and VEGFR2 levels in endothelial cells stimulated with a maximal 
stimulatory dose (0.25 nM) of either VEGF-A165 or VEGF-A121 for 2, 
4, 6, 8, and 24 h (Figure 1C). We used endothelial tubulin levels as a 
control, and such comparisons were used to evaluate varying pro-
tein expression in response to VEGF-A stimulation (Figure 1C). 
Quantification of endothelial VCAM-1 levels revealed a peak of 
VCAM-1 expression after VEGF-A165 stimulation for 8 h correspond-
ing to ∼6.5-fold increase compared with the 0 h time point (Figure 
1D). This peak in VCAM-1 levels was transient and dropped to 
∼2.5-fold rise after VEGF-A165 stimulation for 24 h (Figure 1D). In 
comparison, VEGF-A121 stimulation failed to significantly elevate 
VCAM-1 levels (Figure 1C).
VEGFR2 activation leads to transautophosphorylation of multiple 
tyrosine residues: Y1175 is a key site that undergoes such phospho-
rylation (Takahashi et al., 2001; Holmqvist et al., 2004; Koch et al., 
2011). Monitoring VEGFR2-pY1175 appearance showed that VEGF-
A165 stimulates rapid and transient phosphorylation of this site, 
whereas VEGF-A121 treatment did not produce significant Y1175 
phosphorylation (Figure 1C). VEGF-A-stimulation promotes VEGFR2 
ubiquitination, endocytosis, and proteolysis (Ewan et al., 2006). We 
then asked whether VEGFR2 turnover and synthesis were different 
upon treatment with either VEGF-A165 or VEGF-A121 isoform (Figure 
1E). VEGF-A165 stimulation promoted VEGFR2 degradation over a 
short time period (2–4 h), with VEGFR2 levels reduced by ∼60% after 
2 h (Figure 1E). However, VEGFR2 levels returned to baseline after 
VEGF-A165 stimulation for 8 h (Figure 1E). VEGFR2 levels continued 
on an upward trajectory, with ∼50% increase after VEGF-A165 stimu-
lation for 24 h (Figure 1E). In contrast, VEGF-A121 stimulation ap-
peared to have little effect on VEGFR2 protein levels (Figure 1E). 
These findings show that two different VEGF-A isoforms have differ-
ent capabilities in stimulating the turnover and synthesis of not only 
VEGFR2, but also those of another membrane receptor, VCAM-1.
VEGF-A isoforms differentially regulate multiple signal 
transduction pathways
VEGF-A stimulates multiple MAPK signal transduction pathways in 
endothelial cells (Horowitz and Seerapu, 2012; Koch and Claesson-
Welsh, 2012), which regulate multiple cellular outcomes (Nakatsu 
et al., 2003; Karihaloo et al., 2005; Zhang et al., 2008; Xu et al., 
2011). In this context, we asked whether the increase in endothelial 
VCAM-1 levels (Figure 1D) was linked to altered signal transduction 
pathways activated by the two VEGF-A isoforms, using ligand titra-
tion followed by signal transduction pathway analysis (Figure 2). Ac-
tivation of VEGFR2 and downstream signaling events was first as-
sessed by monitoring transautophosphorylation at cytoplasmic 
residue Y1175 (Figure 2, A and B). Phosphorylation of Y1175 could 
be detected within 5 min of stimulation with either VEGF-A165 or 
VEGF-A121, but there were concentration-dependent effects (Figure 
2A). Quantification showed that VEGF-A121–stimulated VEGFR2-
Y1175 phosphorylation at 0.025 and 0.25 nM was significantly re-
duced (Figure 3B) in comparison to VEGF-A165 (Figure 3A). How-
ever, under saturating conditions of VEGF-A (1.25 nM), the peak 
level of VEGFR2 activation in response to VEGF-A165 (Figure 3A) 
was similar to that induced by VEGF-A121 (Figure 3B).
VEGF-A activates ERK1/2, p38 MAPK, and serine/threonine pro-
tein kinase c-Akt (Akt; also known as protein kinase B) pathways in 
endothelial cells (Koch et al., 2011; Koch and Claesson-Welsh, 
2012). Both VEGF-A165 and VEGF-A121 stimulation promoted a 
rapid and transient peak in ERK1/2 activation within 15 min, with 
differing magnitudes (Figure 2). Quantification showed that VEGF-
A121 stimulation resulted in a generally lower level of peak activation 
(NRPs) NRP1 and NRP2 (Koch et al., 2011). The VEGF-A gene alone 
encodes seven or more different isoforms that bind VEGFR1 (Flt-1), 
VEGFR2 (KDR), and neuropilins (Harper and Bates, 2008). VEGF-A 
gene dose is critical, as heterozygous VEGF-A+/− knockout mouse 
embryos die during embryogenesis (Carmeliet et al., 1996; Keyt 
et al., 1996); VEGFR2−/− knockout mice also exhibit embryonic le-
thality (Shalaby et al., 1995). The most-studied VEGF-A ligand is a 
mature 165-residue processed polypeptide (VEGF-A165), which pro-
motes endothelial cell survival, proliferation, migration, and 
angiogenesis. VEGF-A–regulated endothelial responses are espe-
cially associated with pathological conditions such as tumor pro-
gression (Chung and Ferrara, 2011; Meadows and Hurwitz, 2012).
The binding of VEGF-A to VEGFR2 triggers sustained signal 
transduction, increased trafficking, and proteolysis (Bruns et al., 
2009; Horowitz and Seerapu, 2012; Koch and Claesson-Welsh, 
2012; Nakayama and Berger, 2013). A key aspect of VEGF-A–stimu-
lated reprogramming of endothelial cell function is elevated expres-
sion of 100–200 genes (Schweighofer et al., 2009; Rivera et al., 
2011). VEGF-A–regulated target genes are implicated in a multitude 
of cellular functions, including cell adhesion, signal transduction, 
and transcriptional control. A major question concerns the nature of 
the mechanism(s) that control VEGF-A–stimulated gene expression. 
Although VEGF-A–stimulated signal transduction via MEK1–extra-
cellular signal-regulated kinase 1 and 2 (ERK1/2), 38-kDa stress- and 
mitogen-activated protein kinase (p38 MAPK), and JNK pathways 
could potentially provide multiple means of elevating gene expres-
sion, the exact mechanism by which such signal transduction is inte-
grated with nuclear transcriptional control is unclear. One well-
known target is the membrane receptor vascular cell adhesion 
molecule 1 (VCAM-1), whose expression on endothelial cells pro-
motes binding to leukocyte integrin α4β1 (VLA-4), thus promoting 
endothelial–leukocyte interactions (Jain et al., 1996; Melder et al., 
1996). The mechanism underlying this VEGF-A–stimulated gene ex-
pression is unclear, with studies suggesting roles for NF-κB (Kim 
et al., 2001a) and forkhead (Abid et al., 2008) transcription factors in 
regulating VCAM-1 gene transcription.
A major question is the role of the increasing number of VEGF 
splice isoforms in regulating vascular and animal function. The hu-
man VEGF-A gene alone expresses eight isoforms ranging from 121 
to 206 residues in length. One idea is that the VEGF-A gene en-
codes both proangiogenic and antiangiogenic isoforms that are ex-
pressed in different tissues to modulate the vascular response dur-
ing health and disease (Harper and Bates, 2008). To evaluate the link 
between VEGF-A–stimulated gene expression and isoform func-
tionality, we investigated VCAM-1 expression. Studies on VEGF-
A165 and the VEGF-A isoform 121 residues in length (VEGF-A121) 
showed that these growth factor isoforms differentially activated 
signal transduction pathways linked to a novel event in the nucleus 
that regulates VCAM-1 expression.
RESULTS
VEGF-A isoforms differentially regulate VCAM-1 and 
VEGFR2 turnover and synthesis
The VEGF-A165 isoform promotes increased endothelial VCAM-1 
expression (Melder et al., 1996; Kim et al., 2001a; Schweighofer 
et al., 2009). Although the pathway of VEGF-A–VEGFR2 signal 
transduction is well studied, it is unclear how such events are com-
municated to the nucleus to control nuclear gene transcription, such 
as increased VCAM-1 expression (Figure 1A). To investigate this 
phenomenon, we first asked whether two different VEGF-A isoforms 
that differ in their carboxy-proximal regions (Figure 1B) caused simi-
lar or different effects on VCAM-1 expression levels in primary 
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with either VEGF-A165 or VEGF-A121 (Supplemental Figure S1). 
These data suggest that these two different VEGF-A isoforms have 
differential capabilities not only in stimulating VEGFR2 activation, 
but also in other downstream signal transduction pathways.
VEGF-A isoform–specific stimulation of activating 
transcription factor 2
Exactly how short-term RTK signal transduction integrates with long-
term cellular responses is not well understood (Lemmon and 
Schlessinger, 2010). The VEGFR–VEGF-A axis stimulates intracellu-
lar signaling over a short time frame (0–1 h) and regulates long-term 
endothelial responses such as leukocyte recruitment, cell migration 
(>24 h), and tubulogenesis (5–7 d; Chung and Ferrara, 2011; Koch 
et al., 2011). To identify a nuclear switch that was responsive to 
VEGF-A isoform–specific MAPK signal transduction and could influ-
ence VCAM-1 expression, we focused on activating transcription 
factor 2 (ATF-2), which is known to undergo VEGF-A–stimulated 
phosphorylation in cardiac myocytes and endothelial cells (Seko 
et al., 1998; Salameh et al., 2010). ATF-2 belongs to the basic region 
(Figure 3D) than VEGF-A165 (Figure 3C). Of interest, saturating con-
ditions of VEGF-A, which resulted in similar levels of VEGFR2 peak 
activation (Figure 3, A and B), exhibited approximately twofold dif-
ference in ERK1/2 peak activation between the two isoforms (Figure 
3, C and D). VEGF-A165 and VEGF-A121 also triggered sustained and 
pronounced p38 MAPK activation (Figure 2). Quantification showed 
that VEGF-A121 –stimulated p38 MAPK activation was more pro-
nounced (Figure 3F) than for VEGF-A165 (Figure 3E) under saturating 
ligand conditions. VEGF-A165 and VEGF-A121 also caused differen-
tial Akt activation (Figure 2, A and B). Quantification showed that 
both VEGF-A165 (Figure 3G) and VEGF-A121 (Figure 3H) promoted a 
rapid peak in Akt activation within 15 min. However, VEGF-A165 
(Figure 3G) had greater efficacy than VEGF-A121 (Figure 3H), as a 
much lower concentration of ligand was required to achieve a sig-
nificant response. Of interest, at saturating ligand conditions (1.25 
nM), the peak in Akt activation was comparable between the two 
VEGF-A isoforms (Figure 3, G and H). Further analysis of these data 
sets presented as histograms shows the statistical significance of the 
changes in signal transduction events detected upon stimulation 
FIGURE 1: VEGF-A isoform–specific regulation of VCAM-1 gene expression. (A) Schematic depicting VEGF-A isoform–
specific regulation of VCAM-1 gene expression through modulation of gene transcription in endothelial cells. 
(B) Schematic depicting human VEGF-A–coding mRNA with exons 1–8 and splice variants VEGF-A165 and VEGF-A121. 
(C) Endothelial cells subjected to 0.25 nM VEGF-A165 or VEGF-A121 for the specified times indicated (hours), lysed, and 
probed by immunoblotting to assess phospho-VEGFR2 (VEGFR2-pY1175), VEGFR2, VCAM-1, or tubulin protein levels. 
(D, E) Quantification of (D) VCAM-1 and (E) VEGFR2 protein levels from immunoblotting studies of VEGF-A165–and 
VEGF-A121–stimulated endothelial cells. Error bars indicate ±SEM (n = 3). *p < 0.05, **p < 0.01, ****p < 0.001.
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MAPK is significantly reduced by addition of 
SB203580, which inhibits both the α and β 
forms of p38 MAPK (Figure 4D). Quantifica-
tion of VEGF-A–stimulated phospho–ATF-2 
levels showed that that U0126 (MEK1 inhibi-
tor) but not SB203580 (p38 MAPK inhibitor) 
completely blocked ligand-stimulated phos-
phorylation of ATF-2 (Figure 4E).
A key aspect of growth factor–stimulated 
MAPK activation is nuclear translocation of 
activated protein kinases and phosphoryla-
tion of key substrates, which in turn regulate 
gene transcription (Plotnikov et al., 2011). 
We previously showed that VEGF-A stimula-
tion causes translocation of activated ERK1/2 
into the nucleus of endothelial cells (Jopling 
et al., 2009). To correlate ERK1/2 transloca-
tion with ATF-2 activation, we monitored the 
intracellular distribution of phospho-ERK1/2 
and ATF-2–pT71 using microscopy (Figure 
4F). Activated phospho-ERK1/2 was de-
tected in both the cytoplasm and nucleus 
within 15 min; this also correlated with a 
peak of phospho-ATF-2 in the nucleus 
(Figure 4F). Microscopy analysis of phospho-
ERK1/2 and phospho-ATF-2 in the nucleus 
revealed substantial codistribution of both 
proteins at ∼15 min post–VEGF-A165 stimu-
lation (Figure 4G). Quantification of nuclear 
phospho-ERK1/2 and phospho–ATF-2 
showed a >10-fold rise in codistribution after 
VEGF-A165 stimulation (Figure 4H). Such 
findings show a close link of VEGF-A165–
stimulated MAPK signal transduction lead-
ing to ERK1/2 activation, nuclear transloca-
tion, and downstream activation of ATF-2.
The VEGF-A coreceptor NRP1 has been 
shown to attenuate VEGF-A–stimulated sig-
nal transduction (Pan et al., 2007; Herzog 
et al., 2011). Therefore we evaluated 
whether NRP1 was essential for optimal 
VEGF-A–stimulated ATF-2 activation. Using 
immunoblotting, we monitored ATF-2–pT71 
levels after 15 min of stimulation with either 
VEGF-A165 or VEGF-A121 in NRP1-depleted and control endothelial 
cells (Supplemental Figure S2A). Quantification revealed that both 
VEGF-A165– and VEGF-A121–stimulated ATF-2 activation was re-
duced in NRP1-depleted endothelial cells (Supplemental Figure 
S2B). One consequence of a reduction in NRP1 levels was a con-
comitant reduction in VEGF-A–stimulated ERK1/2 activation (Sup-
plemental Figure S2C). These data suggest that NRP1 influences 
the ability of the VEGFR2–VEGF-A165 complex to effectively activate 
downstream ERK1/2 and thus ATF-2.
VEGF-A and ATF-2 are required for VCAM-1 expression 
and endothelial–leukocyte interactions
VEGF-A–stimulated VCAM-1 gene expression has implicated both 
the NF-κB pathway and forkhead transcription factors (Kim et al., 
2001a,b; Abid et al., 2006; Dejana et al., 2007). On the basis of 
our data, we hypothesized that ATF-2 acts as a nuclear “switch” for 
converting VEGF-A isoform–specific short-term cytosol-to-nucleus 
signaling (via the MEK1-ERK1/2 pathway) into VCAM-1 gene 
subdomain/leucine zipper (bZIP) family of DNA-binding transcrip-
tion factors and undergoes activation upon cellular stress or plasma 
membrane receptor activation (Lau and Ronai, 2012). To determine 
whether VEGF-A isoforms differentially regulate ATF-2 activation, 
we monitored ATF-2–pT71 levels (Figure 4A). Endothelial cells con-
tain basal phospho-ATF-2, which is further elevated upon VEGF-A 
stimulation (Figure 4A). Of note, maximal ATF-2–pT71 levels de-
tected upon VEGF-A165 addition were approximately twofold to 
fivefold higher (Figure 4B) than comparable VEGF-A121 (Figure 4C) 
ligand concentrations.
Multiple signal transduction pathways, including JNK, p38 
MAPK, ERK1/2, and ATM, stimulate phosphorylation at different 
sites on ATF-2 (Lau and Ronai, 2012). To assess whether the increase 
in phospho–ATF-2 was dependent on MEK1-ERK1/2 or p38 MAPK 
pathways, we used cell-permeable small-molecule inhibitors spe-
cific for either pathway (Figure 4D). VEGF-A–stimulated activation of 
ERK1/2 is significantly reduced by addition of U0126, a MEK1 inhibi-
tor (Figure 4D). In contrast, VEGF-A–stimulated activation of p38 
FIGURE 2: VEGF-A isoform–specific activation of signal transduction. (A, B) Endothelial cells 
subjected to different VEGF-A165 or VEGF-A121 concentrations (0, 0.025, 0.25, or 1.25 nM) for 
(A) 5 and 15 min or (B) 30 and 60 min were lysed and probed for phospho-VEGFR2, phospho-
ERK1/2, phospho-p38 MAPK, and phospho-Akt (see Materials and Methods).
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observed for VEGF-A165 (Figure 5B). ATF-2 knockdown substan-
tially reduced the VEGF-A–stimulated increase in VCAM-1 mRNA 
levels by ∼25% (Figure 5B). There is thus a functional requirement 
for the presence of ATF-2 in VEGF-A–stimulated VCAM-1 expres-
sion in endothelial cells.
One question is the link between the requirement for ATF-2 in 
endothelial signal transduction and protein expression. To address 
this, we used immunoblotting to monitor protein levels and phos-
phorylation events 8 h after VEGF-A stimulation in control or ATF-
2–depleted endothelial cells (Figure 5C). This time point of post–
VEGF-A stimulation was used as the point of maximal 
ligand-stimulated VCAM-1 expression (Figure 1D). ATF-2 knock-
down caused ∼75% reduction in ATF-2 protein levels (Figure 5D). 
Activated VEGFR2-pY1175 levels were significantly elevated at this 
transcription, thus modulating VEGF-A isoform–specific long-term 
endothelial responses (including leukocyte recruitment). To evalu-
ate ATF-2 requirement in VEGF-A–stimulated gene transcription, 
we first used specific small interfering RNA (siRNA) duplexes to 
deplete endothelial ATF-2. As expected, ATF-2 mRNA levels were 
depleted only in endothelial cells treated with ATF-2–specific 
siRNA duplexes (ATF-2 knockdown) in comparison to scrambled 
siRNA duplex treatment (control), under both nonstimulated and 
VEGF-A–stimulated conditions (Figure 5A). We then analyzed 
whether ATF-2 depletion affected VCAM-1 mRNA levels (Figure 
5B). On VEGF-A165 stimulation, we detected ∼1.4-fold increase in 
VCAM-1 mRNA levels compared with controls (Figure 5B). VEGF-
A121–stimulated endothelial cells produced ∼1.2-fold increase in 
VCAM-1 mRNA levels, but this was substantially less than that 
FIGURE 3: Quantification of VEGF-A isoform–specific signal transduction. Quantification of (A, B) VEGFR2-pY1175, 
(C, D) ERK1/2-pT202/pY204, (E, F) p38-pT180/pY182, and (G, H) Akt-pS473 levels upon (A, C, E, G) VEGF-A165 or 
(B, D, F, H) VEGF-A121 titration. Error bars indicate ±SEM (n ≥ 4).
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FIGURE 4: VEGF-A isoform–specific intracellular signaling regulates ATF-2 phosphorylation. (A) Immunoblotting of 
VEGF-A–stimulated endothelial cells for ATF-2-pT71, total ATF-2, and tubulin upon ligand titration. (B, C) Quantification 
of phosphorylated ATF-2-pT71 levels upon (B) VEGF-A165 and (C) VEGF-A121 titration. Error bars indicate ±SEM (n = 4). 
(D) Immunoblotting VEGFR2, ATF-2, ERK1/2, and p38 MAPK total and phosphorylated levels after preincubation with 
MEK1 inhibitor (U0126) or p38 MAPK inhibitor (SB203580), followed by VEGF-A isoform (1.25 nM) stimulation for 
15 min. (E) Quantification of ATF-2-pT71 levels upon activation by VEGF-A165 or VEGF-A121 in the presence of MEK1 
inhibitor (U0126) or p38 MAPK inhibitor (SB203580). Error bars indicate ±SEM (n = 3). (F) Endothelial cells stimulated 
with VEGF-A165 for 0, 15, or 30 min were processed for immunofluorescence microscopy using mouse 
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time point but were mirrored by a large de-
crease in VEGFR2 levels (Figure 5C). Differ-
ential phosphorylation in ERK1/2 and phos-
pholipase Cγ1 was also evident (Figure 5C). 
These findings showed that ATF-2 knock-
down did not significantly affect VEGFR2 
turnover and downstream signal transduc-
tion in response to VEGF-A stimulation.
We probed for VCAM-1 expression in 
control or ATF-2–depleted cells 8 h after 
VEGF-A isoform stimulation (Figure 5C). 
VCAM-1 expression was clearly ATF-2 de-
pendent (Figure 5C), and quantification 
highlighted a relatively large (greater than 
threefold) increase in VCAM-1 levels ob-
served upon VEGF-A165 stimulation com-
pared with cells incubated in serum-free or 
complete medium (Figure 5E). Depletion of 
ATF-2 reduced VCAM-1 to baseline levels in 
VEGF-A–stimulated cells (Figure 5E). VEGF-
A121 also stimulated a smaller, 30–40% in-
crease in VCAM-1 protein levels, which was 
also ATF-2 dependent (Figure 5, C and E). 
These data showed that increased VCAM-1 
expression caused by VEGF-A not only was 
ATF-2 dependent but also influenced 
VCAM-1 mRNA levels.
Endothelial VCAM-1 binds leukocyte 
α4β1 integrin (VLA-4) and promotes leuko-
cyte recruitment onto the endothelium be-
fore transendothelial migration (Sixt et al., 
2006; Nourshargh et al., 2010; Reglero-Real 
et al., 2012). A major question is whether 
VEGF-A–stimulated and ATF-2–dependent 
VCAM-1 expression can influence leukocyte 
binding to endothelial cells. To test this idea, 
we used a binding assay that monitored the 
binding of fluorescent-labeled human leuko-
cyte HL-60 cells to an endothelial cell mono-
layer (Figure 5F). VEGF-A165 stimulated 
∼75% increase in leukocyte binding to the 
endothelial monolayer (Figure 5F). However, 
VEGF-A121 caused only a small, ∼15% in-
crease in leukocyte binding to endothelial 
cells (Figure 5F). ATF-2 knockdown com-
pletely ablated VEGF-A–stimulated binding 
of leukocytes to endothelial cells (Figure 5F). 
This phenomenon was VCAM-1 dependent, 
as VCAM-1 knockdown also completely in-
hibited endothelial–leukocyte interactions 
(Figure 5F). These data confirm that the 
VEGF-A–stimulated expression of endothe-
lial VCAM-1 not only is ATF-2 dependent but 
also is sufficient to enable recruitment of leu-
kocytes and enhance cell–cell interactions.
FIGURE 5: ATF-2 requirement for VEGF-A isoform–specific control of VCAM-1 expression in 
endothelial cells. (A, B) Endothelial cells stimulated with 0.25 nM VEGF-A165 or VEGF-A121 in 
different growth conditions for 4 h were analyzed by qRT-PCR for (A) ATF-2 or (B) VCAM-1 
mRNA levels. GAPDH mRNA was used as an internal control. Error bars denote ±SEM (n = 3). 
(C) Endothelial cells subjected to RNA interference and knockdown with either scrambled (Scr) 
or ATF-2–specific (ATF-2) siRNA duplexes were then stimulated with 0.25 nM VEGF-A165 or 
VEGF-A121 for 8 h, lysed, and subjected to immunoblot analysis for a variety of proteins, 
including ATF-2, VEGFR2, and VCAM-1. (D) Quantification of ATF-2 knockdown in endothelial 
cells. Error bars indicate ±SEM (n = 3). (E) Quantification of VCAM-1 levels after 8 h of VEGF-A 
stimulation. Error bars denote ±SEM (n ≥ 3). (F) Endothelial cells treated with scrambled (Scr), 
ATF-2, or VCAM-1 siRNA duplexes were stimulated with 0.25 nM VEGF-A165 or VEGF-A121 (7 h) 
before binding of calcein-labeled, activated HL-60 leukocytes and lysis and measurement (see 
Materials and Methods). Error bars denote ±SEM (n ≥ 3). *p < 0.05, ***p < 0.005.
anti-ERK1/2-pT202/pY204 or rabbit anti-ATF-2-pT71, followed by fluorescence-labeled secondary antibodies. Overlay of 
phospho-ERK1/2 (red) and phospho-ATF-2 (green) staining patterns, with inset box indicating regions of codistribution 
within the nucleus (yellow). Bar, 10 μm. (G) Nuclear codistribution of phospho-ERK1/2 and phospho-ATF-2 (white) 15 min 
poststimulation. (H) Quantification of nuclear phospho-ERK1/2 and phospho-ATF-2 codistribution at 0 and 15 min after 
VEGF-A165 treatment. Error bars indicate ±SEM (n = 3). **p < 0.01.
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question as to the importance of ATF-2 in endothelial cell function 
and responses such as cell migration and tubule formation (tubulo-
genesis). To address this, we first compared the roles of these two 
VEGF-A isoforms in promoting endothelial cell migration, tubulo-
genesis, and ex vivo angiogenesis. VEGF-A165 produced a marked 
dose-dependent stimulation in endothelial cell migration (Supple-
mental Figure S3, A and B) and tubulogenesis (Supplemental Figure 
S3, C and D). However, VEGF-A121 showed a much reduced or mod-
est stimulation in such endothelial cell responses, and such effects 
were especially evident at intermediate or substoichiometric con-
centrations of VEGF-A (Supplemental Figure S3, B and D). Ex vivo 
angiogenesis assays using mouse aortic slices (Supplemental Figure 
S3E) showed VEGF-A165 had approximately threefold higher capac-
ity to stimulate vascular sprouting (Supplemental Figure S3F). Thus 
each VEGF-A isoform had a distinct capacity to promote differential 
endothelial cell outputs; VEGF-A165 was generally more biologically 
active at low or substoichiometric concentrations.
This raised the question as to whether ATF-2 was equally impor-
tant for such differential programming of these endothelial cell re-
sponses. ATF-2 knockdown completely abolished either VEGF-A165– 
or VEGF-A121–stimulated cell migration (Figure 6, A and B). ATF-2 
knockdown also inhibited (∼50%) both VEGF-A165– and VEGF-A121–
stimulated tubulogenesis (Figure 6, C and D). ATF-2 was also re-
quired for endothelial cell proliferation (Supplemental Figure S4). 
Depletion of ATF-2 resulted in a approximately twofold decrease in 
VEGF-A165–stimulated cell proliferation (Supplemental Figure S4). 
Of interest, depletion of ATF-2 also significantly reduced endothelial 
cell proliferation in complete media (Supplemental Figure S4).
Although VCAM-1 was required for endothelial–leukocyte adhe-
sion (Figure 5F), this raised the possibility that it may also be re-
quired for other endothelial responses. To test this idea, we treated 
endothelial cells with scrambled or VCAM-1–specific siRNA du-
plexes before assessing VEGF-A isoform–specific endothelial tubu-
logenesis (Supplemental Figure S5, A and B). There was no signifi-
cant difference in tubulogenesis between control and 
VCAM-1–depleted endothelial cells (Supplemental Figure S5B).
DISCUSSION
In this study, we show that different VEGF-A isoforms have differen-
tial capacities to regulate VCAM-1 gene expression and modulate 
endothelial–leukocyte binding via a novel mechanism (Figure 7). In 
this model, two VEGF-A isoforms with similar binding affinities dif-
ferentially program VEGFR2 activation and downstream signal trans-
duction to act on a common nuclear “switch” that regulates VCAM-1 
expression. This “switch” comprised nuclear ATF-2, a transcription 
factor that is regulated by increased signal transduction from the 
MEK1-ERK1/2 pathway. Our findings show that ATF-2 is an impor-
tant factor that regulates both VEGF-A–regulated responses and 
other essential pathways.
A key feature in VEGF-A–stimulated VCAM-1 expression is the 
requirement for ERK1/2 activation and ATF-2 expression. Maximal 
VCAM-1 expression is dependent on endothelial cell stimulation by 
a specific VEGF-A165 isoform. This isoform greatly increased VEGFR2 
phosphorylation at residue Y1175 in comparison to the VEGF-A121 
isoform. This correlated with an increased ability to promote ERK1/2 
activation and nuclear translocation (Figure 7). Translocation of acti-
vated ERK1/2 into the nucleus revealed close proximity to activated 
phospho–ATF-2. It is feasible that the T71 residue on ATF-2 is di-
rectly phosphorylated by ERK1/2. Alternatively, another target of 
ERK1/2, such as the p90 ribosomal S6 kinase (p90rsk or MAPKAP-
K1), can also translocate into the nucleus and phosphorylate key 
transcription factors (Arthur, 2008; Gerits et al., 2008).
ATF-2 is required for VEGF-A–stimulated endothelial cell 
responses
VEGF-A–stimulated signal transduction regulates diverse long-term 
responses in endothelial cells, such as cell migration and tubulogen-
esis (Chung and Ferrara, 2011; Koch et al., 2011). This raises the 
FIGURE 6: VEGF-A and ATF-2 regulation of endothelial cell 
responses. (A–D) Control, scrambled, or ATF-2–specific siRNA 
duplex–treated endothelial cells were seeded into different assays 
and stimulated with 0.25 nM VEGF-A165 or VEGF-A121 and assessed 
for endothelial cell (A, B) migration or (C, D) tubulogenesis. Bar, 
200 μm (A, B), 400 μm (C, D). Error bars indicate ±SEM (n = 3). 
**p < 0.01, ****p < 0.001.
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ing affinity to VEGFR2 (Keyt et al., 1996; 
Delcombel et al., 2013), but unique recep-
tor–ligand complexes can produce different 
functional outputs. Of interest, it has been 
noted that the murine orthologues of VEGF-
A121 and VEGF-A165 show capacity to dif-
ferentially elevate expression of another cell 
adhesion molecule, ICAM-1, in the mouse 
ocular endothelium (Usui et al., 2004). The 
underlying mechanism regulating such dif-
ferential VEGF-A–regulated ICAM-1 expres-
sion is unknown but raises the speculation 
that ATF-2 may be involved in this phenom-
enon as well. In this context, it is well known 
that different VEGF-A isoforms have the ca-
pacity to trigger differential VEGFR2 activa-
tion and downstream signal transduction 
(Zhang et al., 2000, 2008; Bates et al., 2002; 
Nakatsu et al., 2003; Herve et al., 2005; 
Chen et al., 2010). An important question 
concerns the mechanism underlying VEGF-
A–stimulated gene transcription (Goddard 
and Iruela-Arispe, 2013). STAT3 (Bartoli 
et al., 2003), Egr3 (Liu et al., 2003), forkhead-
like transcription factors (Abid et al., 2006), 
FoxO- and Ets-related factors (Dejana et al., 
2007), and HLX (Testori et al., 2011) have all 
been implicated in regulating VEGF-A–de-
pendent gene transcription.
How ATF-2 regulates VCAM-1 gene 
transcription is intriguing. ATF-2 was origi-
nally identified as a nuclear transcriptional 
switch that was activated upon DNA dam-
age or stress, thus enabling gene expression 
linked to an antiapoptotic response or cell 
proliferation (Lau and Ronai, 2012). The 
ATF-2 polypeptide can undergo phosphory-
lation at different Ser/Thr residues at the N-
terminus (T52, S62, T69, T71, S73, S121) or 
C-terminus (S490, S498; Lau and Ronai, 
2012). One possibility is that phospho–
ATF-2 directly binds to the VCAM-1 pro-
moter to stimulate early gene transcription: 
this may occur via the formation of ATF-2 
homodimers or heterodimers with factors 
such as c-jun. In addition, ATF-2 may recruit 
other factors such as p300 (Kawasaki et al., 
1998) or IRF3 (Panne et al., 2004) to pro-
moter loci, which further modulate target 
gene expression. It has also been proposed that ATF-2 has intrinsic 
histone acetyltransferase activity (HAT) such that it acts to derepress 
gene transcription upon recruitment (Kawasaki et al., 2000), and 
other transcription factors such as NF-κB or forkhead could directly 
stimulate VCAM-1 gene transcription.
Our study shows evidence that different VEGF-A isoforms regu-
late both angiogenesis and inflammation via an ATF-2–dependent 
mechanism. The increased recruitment of activated leukocytes to 
VEGF-A165–stimulated cells, in contrast to VEGF-A121-stimulation, 
argues that this has a functional role in vivo. This could be useful in 
the VEGF-A isoform–specific recruitment of leukocytes into a devel-
oping blood vessel during angiogenesis. This would be useful 
in controlling vascular development and endothelial–leukocyte 
VEGF-A–stimulated intracellular signaling over a short time 
frame (0–2 h) caused early VCAM-1 gene transcription and increased 
mRNA levels (2–8 h) with concomitant peak in VCAM-1 expression 
at the cell surface after 8 h. In this way, short-range signal transduc-
tion is translated into intermediate and long-range effects such as 
membrane protein expression and subsequent interactions that 
modulate endothelial interactions with the environment. A key fea-
ture is that two different VEGF-A isoforms of either 165 or 121 resi-
dues in length show significantly altered ability to promote VCAM-1 
expression. This is largely due to decreased ERK1/2 activation by 
the shorter VEGF-A121 isoform. The different VEGF-A isoforms have 
a conserved N-proximal region (residues 1–111) and variable C-ter-
minus (112–206). Of note, all VEGF-A isoforms display similar bind-
FIGURE 7: A mechanism for VEGF-A isoform–specific regulation of endothelial–leukocyte 
interactions. Schematic describing VEGF-A isoform–specific stimulation of intracellular signaling 
and ATF-2–regulated VCAM-1 gene expression. Numbered steps denote the following: 
1) VEGFR2 activation by either VEGF-A165 or VEGF-A121 programs differential phosphorylation 
of residue Y1175; 2) VEGF-A165 stimulates elevated ERK1/2 phosphorylation and activation 
compared with VEGF-A121; 3) phosphorylated ERK1/2 translocates to the nucleus and regulates 
ATF-2 phosphorylation; 4) VEGF-A165 is more potent than VEGF-A121 in promoting ATF-2 
phosphorylation as a result of increased ERK1/2 activity; 5) VEGF-A165–stimulated ATF-2 activity 
regulates VCAM-1 gene transcription; 6) VCAM-1 gene expression then promotes increased 
endothelial–leukocyte interactions; and 7) VEGF-A–stimulated ATF-2 activity also modulates 
other VEGF-A isoform–specific endothelial responses.
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0.25, or 1.25 nM VEGF-A isoform for the desired time period. Cells 
were then washed three times with ice-cold PBS and lysed in buffer 
with 2% (wt/vol) SDS, Tris-buffered saline, 1 mM phenylmethylsulfo-
nyl fluoride, and protease inhibitor cocktail (Sigma-Aldrich, Poole, 
United Kingdom). Protein concentration was determined using the 
bicinchoninic acid assay (ThermoFisher, Loughborough, United 
Kingdom). A 25 μg amount of protein lysate was subjected to SDS–
PAGE before analysis by immunoblotting. For immunofluorescence 
analysis, cells were serum starved for 3 h before being stimulated 
with VEGF-A165. Cells were fixed and processed as previously de-
scribed (Bruns et al., 2010). Images were acquired using a Delta-
Vision wide-field deconvolution microscope (Applied Precision, 
Issaquah, WA). Relative colocalization was quantified using ImageJ 
(National Institutes of Health, Bethesda, MD) as previously described 
(Bruns et al., 2010; Jopling et al., 2011).
Pharmacological inhibition of signal transduction
Cells were seeded and starved as stated previously, then pretreated 
with 10 μM SB203580 or U0126 (LC Labs, Boston, MA) for 30 min 
before stimulation with 1.25 nM VEGF-A isoform in MCDB131 plus 
0.2% (wt/vol) BSA for 15 min. Cells were then processed via SDS–
PAGE before immunoblot analysis.
Lipid-based transfection of siRNA duplexes
Cells were reversed transfected with siRNA duplexes using Lipo-
fectamine RNAiMAX (Invitrogen, Paisley, United Kingdom). Per well 
of a six-well plate, 15 μl of 2 μM siRNA duplexes was added to 
481 μl of serum/antibiotic-free OptiMEM (Invitrogen) and allowed to 
settle at room temperature for 5 min. Then 4 μl of Lipofectamine was 
added, and the mixture was inverted briefly and incubated at room 
temperature for 20 min. HUVECs were seeded at 2.5 × 105 cells/ml 
in a 1 ml volume of OptiMEM, followed by immediate dropwise 
addition of the siRNA/Lipofectamine mixture. Cells were left at 
room temperature for 30 min before being returned to the incuba-
tor. After 6 h total of incubation, medium was replaced for ECGM. 
Cells were allowed to recover for 72 h before treatment or process-
ing for analysis.
Quantitative reverse transcription PCR
HUVECs were treated with siRNA duplexes specific for either 
ATF-2 or a scrambled (Scr) sequence for 72 h before growth arrest 
induced by overnight serum starvation (serum free) and 2 mM thy-
midine supplementation. Control cells were released for 4 h in full 
growth medium together with either 0.25 nM VEGF-A165 or VEGF-
A121 before extraction of total RNA with the RNeasy Plus Mini Kit 
(Qiagen, Manchester, United Kingdom). A 1 μg total amount of 
RNA was reverse transcribed using the GoScript Reverse 
Transcription System (Promega, Southampton, United Kingdom). 
Real-time quantitative reverse transcription PCR (qRT-PCR) was per-
formed using Power SYBR Green master mix (Applied Biosystems, 
Warrington, United Kingdom) with the following primer sets: glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH; endogenous 
control), forward primer 5′-GTC TCC TCT GAC TTC AAC AGC 
G-3′, reverse primer 5′-ACC ACC CTG TTG CTG TAG CCA A-3’; 
ATF-2, forward primer 5′-GGT AGC GGA TTG GTT AGG ACT 
C-3′, reverse primer 5′TGC TCT TCT CCG ACG ACC ACT T-3′; and 
VCAM-1, forward primer 5′-GAT TCT GTG CCC ACA GTA AGG 
C-3′, reverse primer 5′TGG TCA CAG AGC CAC CTT CTT G-3′. 
qRT-PCR was carried out in multiwell plates run on an ABI 7900HT 
Fast Real-Time PCR System (Applied Biosystems) and gene ex-
pression analyzed using the ΔΔCT method standardized against 
an endogenous control, GAPDH.
balance within a vascular niche. Alternatively, such a phenomenon 
could be extremely useful during pathogenic infection or injury: the 
release of specific VEGF-A isoforms into the damaged vasculature 
not only could promote leukocyte recruitment but also could attune 
leukocyte recruitment to the extent of infection or injury. VEGF-A165 
has been shown to stimulate VCAM-1 expression (Kim et al., 2001a; 
Abid et al., 2006), but this has also been contradicted (Stannard 
et al., 2007). In this context, it has been shown that proinflammatory 
cytokines such as interleukin 1β or tumor necrosis factor α (TNFα) 
promote NF-κB, SP1, AP-1, and IRF recruitment to the VCAM-1 lo-
cus to stimulate VCAM-1 expression (Collins et al., 1995; Weber, 
1996; Hordijk, 2006; Sixt et al., 2006). A link between ATF-2 and NF-
κB has also been proposed in regulating VCAM-1 expression during 
shear stress (Cuhlmann et al., 2011). Expression of a mutant ATF-2 in 
a mouse model has been shown to inhibit VCAM-1 expression 
(Reimold et al., 2001).
The interactions between endothelial cells and leukocytes can 
be subverted in major disease states ranging from atherosclero-
sis, rheumatoid arthritis, and pathogenic infection to cancer. This 
study now provides a mechanism to explain how different VEGF-
A isoforms regulate not only angiogenesis but also inflammation 
in such disease states. Immune cells are well known to secrete 
proangiogenic cytokines such as TNFα and vascular endothelial 
growth factor A (VEGF-A; Griffioen and Molema, 2000; Naldini 
and Carraro, 2005). The angiocrine model postulated by Rafii and 
colleagues suggests that the endothelium secretes soluble and 
membrane-bound factors that act in a paracrine manner on 
neighboring cells to influence vascular development in tissues 
such as liver (Butler et al., 2010; Ding et al., 2010). Our work 
shows that VEGF-A isoforms have unique abilities to instruct the 
endothelium and influence leukocyte recruitment at local sites 
through cell–cell interactions. It will be a challenge to decipher 
the myriad of biological properties of the VEGF family with func-
tional roles in both angiogenesis and inflammation in healthy and 
diseased states.
MATERIALS AND METHODS
Antibodies and growth factors
Antibodies were goat anti-VEGFR2 (R&D Systems, Minneapolis, 
MN), rabbit anti-ERK1/2, mouse anti–phospho-ERK1/2 (Thr202/
Tyr204), rabbit anti-p38, rabbit anti–phospho-p38 (Thr180/Tyr182), rab-
bit anti–phospho-VEGFR2 (Tyr1175), rabbit anti–ATF-2, rabbit anti–
phospho-ATF-2 (Thr71), rabbit anti-NRP1 (Cell Signaling Technology, 
Danvers, MA), mouse anti–α-tubulin, mouse anti–PECAM-1 (CD31; 
Santa Cruz Biotechnology, Santa Cruz, CA), and mouse anti–VCAM-1 
(DAKO, Glostrup, Denmark).
Reagents were as follows. Endothelial cell growth medium 
(ECGM) was from PromoCell (Heidelberg, Germany). Scrambled, 
ATF-2, NRP1, and VCAM1 siRNA duplexes were purchased as 
siGENOME SMARTpools from Dharmacon (Thermo Scientific, 
Lafayette, CO) unless otherwise stated in the figure legends. Re-
combinant human VEGF-A165 was from Genentech (San Francisco, 
CA), and VEGF-A121 was from Promocell.
Cell culture, immunoblotting, and immunofluorescence 
studies
Human umbilical vein endothelial cells (HUVECs) were prepared as 
previously described (Howell et al., 2004). Cells were seeded into 
six-well plates and cultured (for at least 24 h) in ECGM until ∼80% 
confluent, washed three times with phosphate-buffered saline (PBS), 
and then starved in MCDB131 plus 0.2% (wt/vol) bovine serum albu-
min (BSA) for 2–3 h. HUVECs were then stimulated with 0, 0.025, 
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diaphragm and flushed with 500 μl of Hank’s balanced salt solution 
to remove blood products. Fat and fascia were cleaned from the 
aorta by sharp dissection and the vessel sliced into 0.5-mm rings 
with a scalpel. Rings were serum starved overnight at 37°C in 5 ml 
OptiMEM supplemented with penicillin-streptomycin. On ice, 
purified type 1 rat-tail collagen (Millipore, Watford, United King-
dom) was diluted to 1 mg/ml with DMEM before adding 2 μl/ml of 
5 M NaOH. A 55 μl amount of this embedding matrix was pipetted 
per well into a 96-well plate and aortic ring submerged within. Plates 
were left for 15 min at room temperature before incubation at 60 min 
at 37°C. A 150 μl amount of OptiMEM containing 2.5% (vol/vol) FCS 
and penicillin-streptomycin was added per well with appropriate 
VEGF-A. Aortic rings were incubated at 37°C for 5 d with a medium 
change on day 3. Wells were washed with 150 μl of PBS containing 
2 mM CaCl2 and 2 mM MgCl2 and fixed in 4% (vol/vol) Formalin for 
30 min. The collagen was permeabilized with three 15 min washes 
with PBS buffer containing 2 mM MgCl2, 2 mM CaCl2, and 0.25% 
(vol/vol) Triton X-100. Rings were blocked in 30 μl of 1% (wt/vol) BSA 
in PBLEC (PBS containing 100 μM MnCl2, 1% [vol/vol] Tween-20, 
2 mM CaCl2, 2 mM MgCl2) for 30 min at 37°C. A 2.5 μg amount of 
BS1 lectin–fluorescein isothiocyanate (Sigma-Aldrich) in PBLEC was 
added per well, followed by overnight incubation at 4°C. Wells were 
washed three times with 100 μl of PBS containing 2 mM MgCl2, 
2 mM CaCl2, and 0.25% (vol/vol) Triton X-100 and incubated for 2 h 
with 1 μg/ml 4′,6-diamidino-2-phenylindole (in PBLEC). Wells were 
washed three times with 100 μl PBS containing 0.1% (vol/vol) Triton 
X-100 and then with 100 μl of sterile water. Aortic sprouts were 
imaged using an EVOS-fl inverted digital microscope (Life Technolo-
gies). The number of initial sprouts (vascular sprouts emanating di-
rectly from the aortic ring) was counted, and sprout intensity (total 
image intensity − aortic ring intensity) was determined using ImageJ 
software.
Endothelial cell proliferation assay
Two thousand endothelial cells were seeded per well of a 96-well 
plate and left to acclimatize in complete growth medium overnight. 
On the next day, medium was changed and cells starved in 
MCDB131 medium plus 0.2% BSA (wt/vol) for 3 h. Cells were then 
stimulated with the desired concentration of VEGF-A isoforms in a 
final 100 μl volume for 24 h. Bromodeoxyuridine, 10 μM, was added 
per well after 20 h. A cell proliferation enzyme-linked immunosor-
bent assay was then used according to manufacturer’s instructions 
(Roche Diagnostics, Mannheim, Germany). The color change was 
developed using 3,3′,5,5′-tetramethylbenzidine solution and the re-
action quenched with 1 M H2SO 4. Absorbance was measured at 
450 nm using a variable-wavelength 96-well plate reader (Tecan, 
Mannedorf, Switzerland).
Statistical analysis
This was performed using a one-way analysis of variance (ANOVA), 
followed by Tukey’s post hoc test or two-way ANOVA followed by 
Bonferroni multiple comparison test, using Prism software (Graph-
Pad, La Jolla, CA). Significant differences between control and test 
groups were evaluated with *p < 0.05, **p < 0.01, ***p < 0.005, and 
****p < 0.001 indicated on the graphs. Error bars in graphs and 
histograms denote ±SEM.
Leukocyte-binding assay
We labeled 2 × 105 HL-60 leukocytes/well with 0.5 μg/ml calcein 
(Invitrogen) for 30 min at 37°C. Cells were then pelleted and washed 
twice in 5 ml RPMI plus 10% (vol/vol) fetal calf serum (Invitrogen). 
Cells were left for 30 min at 37°C to allow deesterification of calcein 
agent. Then 100 nM phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich, Poole, United Kingdom) was added to the cells and left to 
incubate for 30 min at 37°C. Cells were again pelleted and washed 
twice in 5 ml RPMI. Then 2 × 105 HL-60 leukocytes/well were added 
onto a confluent layer of HUVECs that had been previously stimu-
lated with full growth medium (±VEGF-A165 or VEGF-A121 for 7 h) and 
left to adhere for 1 h at 37°C. Nonadhered leukocytes were removed 
by gentle rinsing with PBS. Cells were then lysed in 200 μl of RIPA 
buffer. Then 50 μl was analyzed by fluorescence excitation at 488 nm 
and emission at 520 nm in a multiwall plate format using a 96-well 
FLUOstar OPTIMA florescence plate reader (BMG LABTECH, Ayles-
bury, United Kingdom). Values were compared with controls where 
VEGF-A was absent.
Cell migration assay
HUVECs were seeded at 3 × 104 cells/well into a 8 μm pore size 
Transwell filter inserted into a 24-well companion plate (BD Biosci-
ences, Oxford, United Kingdom) in MCDB131 plus 0.2% (wt/vol) 
BSA. ECGM or MCDB131 plus 0.2% (wt/vol) BSA containing the 
desired concentration of VEGF-A was added to the lower chambers 
to stimulate cell migration. Cells were allowed to migrate for 24 h 
before being fixed and stained with 0.2% (wt/vol) crystal violet in 
20% (vol/vol) methanol. Nonmigrated cells were then removed from 
the upper chamber using a moist cotton bud. Three to five random 
fields were imaged per Transwell filter and the average number of 
migratory cells calculated.
Tubulogenesis assay
Primary human foreskin fibroblasts (Promocell) were cultured to 
confluency in 48-well plates in Q333 fibroblast growth medium 
(PAA Laboratories, Pasching, Austria). Then 6500 HUVECs were 
seeded onto the fibroblast monolayer in a 1:1 mixture of Q333 and 
ECGM and left for 24 h. Medium was then removed and replaced 
with fresh ECGM ± VEGF-A as desired; medium was replaced ev-
ery 2–3 d for 7 d. Cocultures were then fixed in 200 μl for 20 min 
and blocked in 1% (wt/vol) BSA for 30 min at room temperature. 
Cocultures were then incubated with 1 μg/ml mouse anti-human 
PECAM-1 (CD31; Santa Cruz Biotechnology, Santa Cruz, CA) over-
night at room temperature. Cells were washed three times with 
PBS before incubation with donkey secondary antibody anti-mouse 
Alexa Fluor 594 conjugate (Invitrogen) for 2–3 h at room tempera-
ture. Wells were then washed three times with PBS. Endothelial 
tubules were then visualized by immunofluorescence microscopy 
using an EVOS-fl inverted digital microscope (Life Technologies). 
Five random fields were imaged per well. Both the number of 
branch points and the total tubule length were then quantified 
from each photographic field using the open source software 
AngioQuant (www.cs.tut.fi/sgn/csb/angioquant) and values aver-
aged. For a more detailed method see Fearnley et al. (2014).
Ex vivo aortic sprouting assay
This protocol was adapted from previous studies (Baker et al., 2012). 
All animal and tissue procedures were carried out in accordance 
with United Kingdom Home Office regulations and guidance at 
room temperature unless otherwise stated. Briefly, male wild-type 
C57Bl/6 mice were killed in accordance with United Kingdom Home 
Office regulations. Thoracic aorta was harvested from aortic arch to 
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